Ofatumumab is a medication used in this clinical trial to treat patients with relapsing multiple sclerosis (RMS). It is administered as an injection under the skin every four weeks. The purpose of using ofatumumab in this study is to evaluate its effectiveness in patients who have experienced disease progression despite being treated with other therapies. Ofatumumab works by targeting specific cells in the immune system that are involved in the disease process of multiple sclerosis.

Fumarate-based therapies are a group of medications previously used by patients in this trial before transitioning to ofatumumab. These therapies are designed to help manage relapsing multiple sclerosis by reducing inflammation and the frequency of relapses. They work by modulating the immune system to prevent it from attacking the nervous system.

Fingolimod is another medication that patients in this trial were using before switching to ofatumumab. It is an oral medication that helps control relapsing multiple sclerosis by preventing certain immune cells from reaching the brain and spinal cord, thereby reducing inflammation and the occurrence of relapses.

Relapsing Multiple Sclerosis – Relapsing multiple sclerosis (RMS) is a chronic disease affecting the central nervous system, characterized by episodes of new or worsening neurological symptoms, known as relapses. These relapses are followed by periods of partial or complete recovery, called remissions. The disease can cause a wide range of symptoms, including fatigue, vision problems, muscle weakness, and difficulties with coordination and balance. Over time, the frequency and severity of relapses may vary, and some individuals may experience a gradual worsening of symptoms. RMS is one of the most common forms of multiple sclerosis and can significantly impact daily life and activities. The exact cause of RMS is not fully understood, but it involves an abnormal immune response that damages the protective covering of nerve fibers.